My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 252

    1.

    Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes.

    Peter R, Luzio SD, Dunseath G, Miles A, Hare B, Backx K, Pauvaday V, Owens DR.

    Diabetes Care. 2005 Mar;28(3):560-5.PMID: 15735188 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.

    Ashwell SG, Gebbie J, Home PD.

    Diabet Med. 2006 Aug;23(8):879-86.PMID: 16911626 [PubMed - indexed for MEDLINE]Related articles

    3.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.

    Luzio SD, Beck P, Owens DR.

    Horm Metab Res. 2003 Jul;35(7):434-8.PMID: 12931275 [PubMed - indexed for MEDLINE]Related articles

    5.

    Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.

    Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.

    Diabet Med. 2006 Mar;23(3):285-92.PMID: 16492212 [PubMed - indexed for MEDLINE]Related articles

    6.

    Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

    Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.

    Diabetes Care. 2007 Oct;30(10):2447-52. Epub 2007 Jul 10. Erratum in: Diabetes Care. 2008 Jan;31(1):188. PMID: 17623819 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.

    Kazda C, Hülstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M.

    J Diabetes Complications. 2006 May-Jun;20(3):145-52.PMID: 16632233 [PubMed - indexed for MEDLINE]Related articles

    8.

    No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes.

    Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L.

    Diabet Med. 2002 Jun;19(6):490-5.PMID: 12060061 [PubMed - indexed for MEDLINE]Related articles

    9.

    Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

    Ann Intern Med. 2008 Oct 21;149(8):531-9.PMID: 18936501 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    12.

    A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.

    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.

    Pediatrics. 2008 Mar;121(3):e466-72. Epub 2008 Feb 25.PMID: 18299307 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.

    Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smedegaard JS, Lauritzen T, Christiansen JS.

    Diabet Med. 2008 May;25(5):585-91.PMID: 18445172 [PubMed - indexed for MEDLINE]Related articles

    14.

    Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.

    Karges B, Muche R, Riegger I, Moritz M, Heinze E, Debatin KM, Wabitsch M, Karges W.

    Clin Ther. 2006 Dec;28(12):2094-101.PMID: 17296465 [PubMed - indexed for MEDLINE]Related articles

    15.

    Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.

    Fulcher GR, Gilbert RE, Yue DK.

    Intern Med J. 2005 Sep;35(9):536-42.PMID: 16105155 [PubMed - indexed for MEDLINE]Related articles

    16.

    Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.

    Ashwell SG, Gebbie J, Home PD.

    Diabet Med. 2006 Jan;23(1):46-52.PMID: 16409565 [PubMed - indexed for MEDLINE]Related articles

    17.

    Dosing of insulin glargine in the treatment of type 2 diabetes.

    Barnett A.

    Clin Ther. 2007 Jun;29(6):987-99. Review.PMID: 17692716 [PubMed - indexed for MEDLINE]Related articles

    18.

    Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

    Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R.

    Diabetes Care. 2000 Jun;23(6):813-9.PMID: 10841002 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).

    Kanazawa Y, Igarashi Y, Komiya K, Sakurai Y, Shimizu T, Fujitani Y, Tanaka Y, Watada H, Kawamori R, Hirose T.

    Endocr J. 2007;54(6):975-83. Epub 2007 Nov 14.PMID: 18000343 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity